BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Revatio (sildenafil) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Revatio (sildenafil)\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07391579-517@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Revatio (sildenafil): Phase 4 readout est. (NCT07391579)
DESCRIPTION:Revatio (sildenafil)\, phase 4.\nStudy: Daily Tadalafil 5 mg Co
 mbined With On-Demand Sildenafil 100 mg for Treatment of Erectile Dysfunct
 ion in PDE-5I Non Responder Patients\nEstimated primary completion: Decemb
 er 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/sildenafil#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07391
 579
URL:https://assetmemo.bio/drug/sildenafil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04565925-517@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Revatio (sildenafil): Phase 2 readout est. (NCT04565925)
DESCRIPTION:Revatio (sildenafil)\, phase 2.\nStudy: Sildenafil for Treatmen
 t of Urinary Incontinence in Patients With Spinal Cord Injuries\nEstimated
  primary completion: 1 December 2026. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/sildenafil#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT04565925
URL:https://assetmemo.bio/drug/sildenafil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05061368-517@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Revatio (sildenafil): Phase 2 readout est. (NCT05061368)
DESCRIPTION:Revatio (sildenafil)\, phase 2.\nStudy: Oral Sildenafil for Exe
 rcise Capacity\, Dyspnea and Cardiopulmonary Function in COPD\nEstimated p
 rimary completion: May 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/sildenafil#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05061368
URL:https://assetmemo.bio/drug/sildenafil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07647003-517@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270502
DTEND;VALUE=DATE:20270503
SUMMARY:Revatio (sildenafil): Phase 2 readout est. (NCT07647003)
DESCRIPTION:Revatio (sildenafil)\, phase 2.\nStudy: A Study to Evaluate the
  Effect of Two Fixed-Dose Leucine\, Sildenafil and Metformin Combinations 
 on Blood Pressure in Individuals With Hypertension\nEstimated primary comp
 letion: 2 May 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/s
 ildenafil#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07647003
URL:https://assetmemo.bio/drug/sildenafil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06324396-517@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Revatio (sildenafil): Phase 1 readout est. (NCT06324396)
DESCRIPTION:Revatio (sildenafil)\, phase 1.\nStudy: IMProving DRug Dosing a
 nd Outcomes for Single VEntricle Patients With Fontan Associated Liver Dis
 ease\nEstimated primary completion: 31 May 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/sildenafil#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06324396
URL:https://assetmemo.bio/drug/sildenafil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07508358-517@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Revatio (sildenafil): Phase 1 readout est. (NCT07508358)
DESCRIPTION:Revatio (sildenafil)\, phase 1.\nStudy: Vaginal Sildenafil for 
 Primary Dysmenorrhea\nEstimated primary completion: June 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/sildenafil#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07508358
URL:https://assetmemo.bio/drug/sildenafil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06810284-517@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Revatio (sildenafil): Phase 2 readout est. (NCT06810284)
DESCRIPTION:Revatio (sildenafil)\, phase 2.\nStudy: Sildenafil Plus Hypothe
 rmia to Treat Neonatal Encephalopathy\nEstimated primary completion: June 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/sildenafil#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06810284
URL:https://assetmemo.bio/drug/sildenafil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05782244-517@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Revatio (sildenafil): Phase 2 readout est. (NCT05782244)
DESCRIPTION:Revatio (sildenafil)\, phase 2.\nStudy: Sildenafil for Microvas
 culopathy in Chronic TBI\nEstimated primary completion: 31 December 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/sildenafil#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05782244
URL:https://assetmemo.bio/drug/sildenafil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07824674-517@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Revatio (sildenafil): Phase 2/3 readout est. (NCT07824674)
DESCRIPTION:Revatio (sildenafil)\, phase 2/3\, Pulmonary Arterial Hypertens
 ion.\nStudy: The Effect of Additive On-Demand Sildenafil vs. Dextrose Cand
 y on Maximum Exercise Capacity in Pulmonary Arterial Hypertension\nEstimat
 ed primary completion: April 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/sildenafil#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07824674
URL:https://assetmemo.bio/drug/sildenafil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07039760-517@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Revatio (sildenafil): Phase 1 readout est. (NCT07039760)
DESCRIPTION:Revatio (sildenafil)\, phase 1.\nStudy: Asciminib With or Witho
 ut Sildenafil for Brain Tumors\nEstimated primary completion: 30 April 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/sildenafil#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07039760
URL:https://assetmemo.bio/drug/sildenafil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06649539-517@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Revatio (sildenafil): Phase 4 readout est. (NCT06649539)
DESCRIPTION:Revatio (sildenafil)\, phase 4.\nStudy: Delayed Dose Collagenas
 e Clostridium Histolyticum (CCH) Protocol for Men With Peyronie's Disease\
 nEstimated primary completion: October 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/sildenafil#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06649539
URL:https://assetmemo.bio/drug/sildenafil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06510322-517@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Revatio (sildenafil): Phase 1 readout est. (NCT06510322)
DESCRIPTION:Revatio (sildenafil)\, phase 1.\nStudy: Sildenafil to Reduce Va
 scular Remodeling During Left Ventricular Assist Device Support\nEstimated
  primary completion: December 2029. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/sildenafil#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06510322
URL:https://assetmemo.bio/drug/sildenafil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06123156-517@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20300228
DTEND;VALUE=DATE:20300301
SUMMARY:Revatio (sildenafil): Phase 3 readout est. (NCT06123156)
DESCRIPTION:Revatio (sildenafil)\, phase 3.\nStudy: Interest of Early Erect
 ile Rehabilitation With Sildenafil After Radiotherapy and Proctectomy for 
 Rectal Cancer\nEstimated primary completion: February 2030. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/sildenafil#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06123156
URL:https://assetmemo.bio/drug/sildenafil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06800092-517@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Revatio (sildenafil): Phase 2/3 readout est. (NCT06800092)
DESCRIPTION:Revatio (sildenafil)\, phase 2/3.\nStudy: Sildenafil to Prevent
  and Reduce Cancer Related Cognitive Impairment\nEstimated primary complet
 ion: 1 June 2030. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sil
 denafil#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06800092
URL:https://assetmemo.bio/drug/sildenafil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06098833-517@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Revatio (sildenafil): Phase 2 readout est. (NCT06098833)
DESCRIPTION:Revatio (sildenafil)\, phase 2.\nStudy: Treatment of Neonatal E
 ncephalopathy With Oral Sildenafil Suspension to Repair Brain Injury Secon
 dary to Birth Asphyxia\nEstimated primary completion: October 2030. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/sildenafil#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06098833
URL:https://assetmemo.bio/drug/sildenafil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
